Industry
Biotechnology
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Loading...
Open
1.13
Mkt cap
2.6M
Volume
133K
High
1.13
P/E Ratio
N/A
52-wk high
42.35
Low
1.06
Div yield
N/A
52-wk low
1.04
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
July 18, 2024 | 3:21 pm
Portfolio Pulse from Benzinga Newsdesk
July 18, 2024 | 3:20 pm
Portfolio Pulse from Benzinga Insights
May 21, 2024 | 7:15 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 12:37 pm
Portfolio Pulse from Avi Kapoor
April 29, 2024 | 5:04 pm
Portfolio Pulse from Benzinga Newsdesk
April 29, 2024 | 2:07 pm
Portfolio Pulse from Benzinga Newsdesk
April 29, 2024 | 1:02 pm
Portfolio Pulse from Avi Kapoor
April 26, 2024 | 5:56 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.